Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 286

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 286
---
center'>149</div>

DiamiR’s data was also presented at numerous
scientific and industry conferences, most recently:

Child Neurology Society, October 2023, Vancouver,
Canada,

Rett Syndrome Foundation Research Trust Conference,
September 2023, Boston MA,

Alzheimer’s Association International Conference
2023, Amsterdam, Netherlands,

15Clinical Trials on Alzheimer’s
Disease (CTAD), San Francisco, CA,

Alzheimer’s Association International Conference
2022, San Diego, CA.

Grants and Awards

Since its inception, DiamiR has raised over $9.7
million grant funding from government agencies and disease foundations. On October 1, 2020, DiamiR announced that it received two grants
from the National Institutes of Health (NIH) in the total amount of approximately $3.86 million. The National Institute on Aging (NIA)
awarded DiamiR approximately $3.36 million in a Commercialization Readiness Pilot (CRP) grant as part of its Small Business Innovation
Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration with leading academic centers and
continues to support development of CogniMIR, DiamiR’s lead diagnostic product candidate for early detection and
monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR by the National Institute for Neurological
Disorders and Stroke (NINDS) for a project entitled “Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome.”

DiamiR has received non-dilutive
funding to support its work. Below is a summary of DiamiR’s awards to date:

| * | indicates grants from the National Institutes of Health (NIH). |

<div align='center'>150</div>

NIH/NIA SBIR CRP Grant Number 2R44AG044860-07
09/01/2020 – 04/30/2024

Title: Brain-enriched microRNAs detectable in
plasma as biomarkers of Alzheimer’s disease

Analytical validation of CogniMIR® miRNA panel,
and other studies supporting commercialization of the test within a CLIA/CAP laboratory.

NIH/NINDS SBIR Phase I Grant Number R43NS115212.
09/30/2020 – 03/30/2023

Title: Circulating organ-enriched micro